Christopher McAleer - AIM ImmunoTech Scientific Officer
| 0A4Y Stock | 0.23 0.02 9.52% |
Executive
Christopher McAleer is Scientific Officer of AIM ImmunoTech
| Address | 2117 SW Highway 484, Ocala, FL, United States, 34473 |
| Phone | 352 448 7797 |
| Web | https://aimimmuno.com |
AIM ImmunoTech Management Efficiency
The company has return on total asset (ROA) of (0.8004) % which means that it has lost $0.8004 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5479) %, meaning that it generated substantial loss on money invested by shareholders. AIM ImmunoTech's management efficiency ratios could be used to measure how well AIM ImmunoTech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, AIM ImmunoTech's Total Assets are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 60.6 M in 2024, whereas Other Current Assets are likely to drop slightly above 611.2 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Brendan Ittelson | Zoom Video Communications | N/A | |
| Gary Sorrentino | Zoom Video Communications | N/A | |
| Charlotte Almberg | Coor Service Management | N/A | |
| Michael Tamlin | Neometals | N/A | |
| Aparna Esq | Zoom Video Communications | 45 | |
| Paul Wallwork | Neometals | N/A | |
| Anna Ahlberg | Surgical Science Sweden | 54 | |
| Christian Reiche | Neometals | N/A | |
| Katarina Andersson | Coor Service Management | N/A | |
| Shane Crehan | Zoom Video Communications | 50 | |
| Darren Townsend | Neometals | 55 | |
| Ryan Azus | Zoom Video Communications | 48 | |
| James Waghorn | Sancus Lending Group | N/A | |
| Amanda Virgilio | Neometals | N/A | |
| Peter Viinapuu | Coor Service Management | 60 | |
| Chris Tanner | JLEN Environmental Assets | N/A | |
| Doron Zilberman | Surgical Science Sweden | 62 | |
| Jane Tang | JLEN Environmental Assets | N/A | |
| Sofia Nilsson | Coor Service Management | N/A | |
| Daniel Evestedt | Surgical Science Sweden | 47 | |
| Inbal MazorBadichi | Surgical Science Sweden | 55 | |
Management Performance
| Return On Equity | -1.55 | ||||
| Return On Asset | -0.8 |
AIM ImmunoTech Leadership Team
Elected by the shareholders, the AIM ImmunoTech's board of directors comprises two types of representatives: AIM ImmunoTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AIM. The board's role is to monitor AIM ImmunoTech's management team and ensure that shareholders' interests are well served. AIM ImmunoTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AIM ImmunoTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| III Esq, Exec COO | ||
| Esq JD, CEO Chairman | ||
| Ann Coverly, Director Coordinator | ||
| MBA IV, Chief Officer | ||
| Jodie Pelz, Director Finance | ||
| Christopher McAleer, Scientific Officer | ||
| David MD, Chief Director | ||
| Ralph Cavalli, Vice Manufacturing | ||
| Carol Smith, Chief Officer |
AIM Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AIM ImmunoTech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.55 | ||||
| Return On Asset | -0.8 | ||||
| Operating Margin | (73.88) % | ||||
| Current Valuation | 6.55 M | ||||
| Shares Owned By Insiders | 8.57 % | ||||
| Shares Owned By Institutions | 14.07 % | ||||
| Revenue | 201 K | ||||
| Gross Profit | (715 K) | ||||
| EBITDA | (31.36 M) | ||||
| Net Income | (19.45 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for AIM Stock Analysis
When running AIM ImmunoTech's price analysis, check to measure AIM ImmunoTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AIM ImmunoTech is operating at the current time. Most of AIM ImmunoTech's value examination focuses on studying past and present price action to predict the probability of AIM ImmunoTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AIM ImmunoTech's price. Additionally, you may evaluate how the addition of AIM ImmunoTech to your portfolios can decrease your overall portfolio volatility.